Loading...

YAKUODO HOLDINGS Co., Ltd.

7679.TJPX
Healthcare
Medical - Pharmaceuticals
¥2327.00
¥7.00(0.30%)

YAKUODO HOLDINGS Co., Ltd. (7679.T) Financial Performance & Income Statement Overview

Analyze YAKUODO HOLDINGS Co., Ltd. (7679.T) financial statements (income, balance sheet, and cash flow) across both yearly and quarterly periods.

Revenue Growth
6.83%
6.83%
Operating Income Growth
5.26%
5.26%
Net Income Growth
11.76%
11.76%
Operating Cash Flow Growth
-20.24%
20.24%
Operating Margin
3.61%
3.61%
Gross Margin
20.01%
20.01%
Net Profit Margin
2.81%
2.81%
ROE
12.02%
12.02%
ROIC
10.25%
10.25%

YAKUODO HOLDINGS Co., Ltd. (7679.T) Income Statement & Financial Overview

View the income breakdown for YAKUODO HOLDINGS Co., Ltd. 7679.T across both annual and quarterly reports.

MetricQ4 2024Q3 2024Q2 2024Q1 2024
Revenue$37.42B$37.74B$40.17B$36.63B
Cost of Revenue$30.11B$29.59B$32.39B$29.46B
Gross Profit$7.31B$8.15B$7.77B$7.17B
Gross Profit Ratio$0.20$0.22$0.19$0.20
R&D Expenses$0.00$0.00$0.00$0.00
SG&A Expenses$6.41B$6.76B$6.00B$5.76B
Operating Expenses$6.41B$6.76B$6.00B$5.76B
Total Costs & Expenses$36.52B$36.35B$38.39B$35.22B
Interest Income$7.00M$0.00$5.00M$3.00M
Interest Expense$28.00M$0.00$17.00M$16.00M
Depreciation & Amortization$770.00M$704.75M$725.00M$707.00M
EBITDA$1.68B$2.10B$2.59B$2.21B
EBITDA Ratio$0.04$0.06$0.06$0.06
Operating Income$908.00M$1.39B$1.78B$1.40B
Operating Income Ratio$0.02$0.04$0.04$0.04
Other Income/Expenses (Net)-$29.00M$78.00M$69.00M$79.00M
Income Before Tax$879.00M$1.47B$1.85B$1.48B
Income Before Tax Ratio$0.02$0.04$0.05$0.04
Income Tax Expense-$21.00M$457.00M$513.00M$455.00M
Net Income$899.00M$1.01B$1.33B$1.03B
Net Income Ratio$0.02$0.03$0.03$0.03
EPS$45.88$51.80$68.08$52.41
Diluted EPS$45.88$51.80$68.08$52.41
Weighted Avg Shares Outstanding$19.59M$19.59M$19.59M$19.59M
Weighted Avg Shares Outstanding (Diluted)$19.59M$19.59M$19.59M$19.59M

The company's financials show resilient growth, with revenue advancing from $36.63B in Q1 2024 to $37.42B in Q4 2024. Gross profit remained healthy with margins at 20% in Q4 2024 compared to 20% in Q1 2024. Operating income hit $908.00M last quarter, sustaining a consistent 2% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at $1.68B. Net income dropped to $899.00M, while earnings per share reached $45.88. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.

Unlock 25+ Years of Financial Data

Get access to extended historical data, advanced metrics, and more with our premium plan

Frequently Asked Questions

;